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Abstract
Introduction: Urinary iodine concentrations were analyzed in the morning urine samples of patients with differentiated thyroid cancer
(DTC).
Material and methods: The analyzed group included 572 DTC patients who were treated with radioiodine or hospitalized for evaluation
of radioiodine treatment effects in 2009 at the Institute of Oncology in Gliwice. Ioduria was analyzed by PAMM (Program Against Micro-
nutrient Malnutrition) method before rhTSH administration. A total of 545 tests were performed during L-thyroxine treatment and
27 after L-thyroxine withdrawal.
Results: Median L-thyroxine dose was 150 µg/day. Median ioduria was 127.5 µg/L during L-thyroxine therapy and 134 µg/L after the
L-thyroxine withdrawal. No distinct relation between ioduria and L-thyroxine dose was observed. Ioduria < 200 µg/L was observed in
over 90% of patients and this cut-off was chosen for the reference range. Only 1.2% of patients showed a distinct stable iodine contamina-
tion (ioduria ≥ 300 µg/L).
Conclusions: Urinary iodine concentrations in differentiated thyroid cancer patients treated with L-thyroxine vary in a wide range and do
not show a clear relation with L-thyroxine dose. (Pol J Endocrinol 2010; 61 (5): 458–461)
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Streszczenie
Wstęp: W pracy przeanalizowano stężenie jodu w porannej próbce moczu u chorych na zróżnicowanego raka tarczycy (DTC, differentia-
ted thyroid cancer).
Materiały i metody: Badano 572 chorych na DTC po operacji, którzy w 2009 roku byli hospitalizowani w celu leczenia jodem radioaktyw-
nym lub oceny jego wyników. Stężenie jodu w moczu oznaczano metodą PAMM (Program Against Micronutrient Malnutrition).
W trakcie leczenia L-tyroksyną wykonano 545 badań, 27 po przerwie w stosowaniu L-tyroksyny.
Wyniki: Mediana dawki L-tyroksyny wynosiła 150 µg/dzień. Mediana dobowego wydalania jodu z moczem wynosiła 127,5 µg/L, a po
odstawieniu L-tyroksyny 134 µg/L. Nie obserwowano zależności stężenia jodu w moczu od stosowanej dawki tyroksyny. Jodurię < 200 µg/L
obserwowano u ponad 90% chorych i ten zakres uznano za referencyjny. Kontaminację stabilnym jodem wykazano u 1,2% (joduria ≥ 300 µg/L).
Wnioski: Stężenia jodu w moczu u chorych na zróżnicowanego raka tarczycy, leczonych L-tyroksyną, wahają się w szerokim przedziale
wartości i nie korelują z dawką L-tyroksyny. (Endokrynol Pol 2010; 61 (5): 458–461)
Słowa kluczowe: rak tarczycy, joduria, terapia L-tyroksyną
Introduction
Low iodine diet is not routinely administered in Polish
patients with differentiated thyroid cancer (DTC), due
to the moderate iodine deficiency in our country. Since
iodine deficiency has been compensated for since the
late nineties, the question of low iodine diet arises again.
The assessment of urinary iodine concentration is
not routinely indicated in differentiated thyroid cancer
(DTC) patients before planned radioiodine therapy or
diagnostic radioiodine scan. However, its range should
be known in every population of patients to define the
indication for iodine diet preceding therapy and to avoid
risk of interference with radioiodine therapy [1–5]. Also,
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the increasingly frequent use of rhTSH to support radio-
iodine therapy and diagnostics raises questions about
ioduria during rhTSH-supported procedures.
The aim of the study was to analyze urinary iodine
concentrations in DTC patients treated with radioio-
dine, or followed-up after radioiodine therapy during
L-thyroxine treatment with the end of rhTSH, at the
Institute of Oncology in Gliwice.
Material and methods
The analyzed group involved 572 DTC patients who were
treated with radioiodine or followed up with 131I scan
after previous radioiodine therapy from April 17 to De-
cember 12 2009 at the Institute of Oncology in Gliwice.
The age range of patients was 10–87 years. Median
age was 51 years. 545 tests were performed during
L-thyroxine therapy under rhTSH administration and
27 after L-thyroxine withdrawal. The group of patients
with L-thyroxine withdrawal stopped L-T4 intake
5 weeks before radioiodine treatment then used L-T3
for 3 weeks and after that used no thyroid hormone
supplementation for 2 weeks. In the group under rhTSH
administration, the recombinant TSH was injected two
times in a 24-hour time interval and L-T4 therapy was
given during the whole treatment process.
Median L-thyroxine dose was 150 µg/day (range
50-250 µg/day). Median TSH serum level in patents
under rhTSH administration was: 0.039 mU/L before
rhTSH administration, 176 mU/L on the next day after
the second rhTSH administration, and in patents after
L-thyroxine withdrawal it was 33 mU/L.
Iodine urine concentration was analyzed using the
PAMM method (Program Against Micronutrient Mal-
nutrition) based on measurement of the Sandell-
Kolthoff reaction. This method is based on spectropho-
tometer analysis of the catalytic properties of iodine in
reaction with Ce (IV) and As (III). As (III) reduces Ce (IV)
to Ce (III) and iodine works as a catalyst of this reaction
(the greater amount of iodine the quicker reaction is).
The solution of cerium ions (IV) is orange and shows
light absorption at 405 nm wavelength whereas the so-
lution cerium (III) is colourless. It gives the opportunity
to follow the reaction kinetics by the measurement of
absorbance, and the reaction rate is a function of the
iodine concentration. The colour change that occurs
during the reaction can therefore be used to determine
the iodine concentration in an unknown urine speci-
men, when compared to a set of known iodine stan-
dards. Due to possible interference coming from com-
ponents of urine matrix, the pretreatment stage needs
mineralization by the use of potassium chlorate (V).
Results
The median urinary iodine concentration was 127.5 µg/L
and ranged from 10.1 to 395.2 µg/L. In patients investi-
gated after the L-thyroxine withdrawal, median urinary
iodine concentration was 134 µg/L and ranged from
10.1 to 345.1 µg/L. There were no differences between
patients treated during and patients treated off L-T4
therapy. These results, ranked from the lowest to the
highest, are shown in Figure 1.
Only a small fraction of patients exhibited iodine
urinary concentrations > 200 µg/L and a few (1.2%) ex-
ceeded 300 µg/L (Fig. 2). Interestingly, no difference be-
tween L-thyroxine withdrawal patients and patients in-
vestigated during L-T4 therapy was noted. Although half
of them are in the low range (< 100 µg/L), the other 50%
are dispersed within the upper half of the range (Fig. 3).
No distinct relation between urinary iodine and
L-thyroxine dose administered was observed (Fig. 4).
There was also no relation between urinary iodine and
TSH serum level.
Discussion
Our study is consistent with recently published Italian data
showing no significant differences in iodine excretion be-
tween patients on or off L-T4. According to the authors’
Figure 1. The distribution of urinary iodine concentration in DTC
patients
Rycina 1. Rozkład stężenia jodu w moczu u chorych na DTC
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opinion the body iodine content is not an important de-
terminant of thyroid ablation when preparing patients
with either L-T4 withdrawal or on rhTSH [1].
Our data show that iodine urinary concentrations
in DTC patients treated with suppressive L-thyroxine
doses are high and do not change depending on LT4
dose or L-T4 withdrawal. Similarly, Barbaro et al. dem-
onstrated that L-T4 withdrawal was related to a slight
reduction in urinary iodine level only, with no impact
on the 131I treatment effectiveness [2], while low iodine
diet increased the sensitivity of radioiodine-avid foci
detection [3–5].
Currently, in most of DTC patients, rhTSH is applied
without the necessity of L-thyroxine (containing stable
iodine) withdrawal. Thus, the question arises whether
low iodine diet before radioiodine administration in
order to increase 131I uptake should be recommended.
Our results showing no relation of urinary iodine with
L-thyroxine doses do not support this assumption.
The majority of papers confirming the relevance of
low iodine diet before radioiodine administration for
diagnostic or therapeutic purposes have been published
in the early eighties [3–10]. In many countries low io-
dine diet is a standard procedure applied to DTC pa-
tients before radioiodine administration. However, un-
til recently, low iodine diet was not routinely recom-
mended in Poland due to iodine deficiency and low
iodine content in food. The introduction of this recom-
mendation without evidence-based data supporting its
use seems precautious.
In DTC patients on L-T4 suppressive treatment the
reference urinary iodine concentration should not ex-
tend 200 µg/L [11, 12]. Published data suggest that con-
tamination with stable iodine is present when iodine
urinary level is > 300 µg/L [13]. This was stated only in
the minority (1.2%) of our patients. However, iodine
urinary excretion > 200 µg/L may also be related to high-
er risk of false negative whole body scintigraphy.
Figure 2. The ratio of patients showing stable iodine contamination
(urinary iodine was ≥ 300 µg/L)
Rycina 2. Tylko u 1,2% badanych stwierdzono kontaminację
jodem stabilnym (joduria wynosiła ≥ 300 µg/l)
Figure 3. Urinary iodine concentrations under rhTSH administration on L-T4 therapy and after L-T4 withdrawal. The dots represent
urinary iodine values in patients after L-thyroxine withdrawal
Rycina 3. Stężenie jodu w moczu na stymulacji z użyciem rhTSH (w trakcie stosowania L-T4) i po odstawieniu L-tyroksyny (zaznaczone
punktami)
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Figure 4. Urinary iodine concentrations (µg/L) and corresponding L-thyroxine doses (µg/day) in DTC patients
Rycina 4. Wzrastające stężenia jodu w moczu (µg/l) i odpowiadające im dawki L-tyroksyny (µg/d.) u chorych na DTC
Distant DTC metastases are currently rarely ob-
served in Poland [14, 15]. The low incidence of stable
iodine contamination (only 1.2% of DTC patients with
urinary iodine concentration > 300 µg/L in our study)
indicate that low iodine diet during rhTSH administra-
tion before radioiodine diagnostics and treatment may
be considered non-obligatory. Nevertheless, because of
higher iodine content in food, the recommendation of
low iodine diet before radioiodine administration may
be necessary in future.
Conclusions
1. In general, the iodine excretion by urine in DTC pa-
tients treated with thyroxine with the intention of
TSH suppression is high and does not change with
L-thyroxine dose or after L-thyroxine withdrawal.
These observations suggest that a low iodine diet
would not be effective either.
2. Urinary iodine concentrations > 200 µg/L, and par-
ticularly > 300 µg/L, may be connected with a risk
of false negative radioiodine scan or ineffective ra-
dioiodine therapy, and in this group of patients low
iodine diet before second treatment may be indicated.
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